Visão geral da empresa
A clinical-stage oncology enterprise known as Boundless Bio, Inc. is dedicated to developing interrogating extrachromosomal DNA (ecDNA) directed therapies aimed at treating patients suffering from oncogene amplified cancers. The company operates within the Healthcare sector, specifically functioning inside the Biotechnology industry, which defines its focus on high-risk, high-reward scientific research and drug development rather than immediate product commercialization. Boundless Bio, Inc. currently possesses a market capitalization of $25.54M and maintains an organizational structure with 28 employees. These valuation and staffing figures indicate a micro-cap status typical of early-stage biotechnology firms that are heavily reliant on external capital to fund their clinical pipelines before generating substantial commercial revenue streams.
Saúde financeira
The company reports a Net Income (TTM) of $-58,197,000 and an EBITDA of $-62,301,000, while Revenue (TTM) is listed as N/A, revealing a cost structure where operating expenses significantly exceed any current top-line generation. With a Free Cash Flow of $-31,409,000, the company demonstrates a cash burn rate that necessitates continuous financing to sustain operations and advance its lead product candidate, BBI-940. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which indicates that the company is not yet profitable and that current revenue does not cover direct costs or operating expenses to generate a surplus. The balance sheet shows a Cash position of $107.58M against Total Debt of $49.03M, resulting in a Debt to Equity ratio of 49.70, suggesting a leveraged position relative to equity but providing substantial liquidity reserves to weather long development cycles. A Current Ratio of 8.74 signals robust short-term liquidity, meaning the company holds significantly more current assets than current liabilities, ensuring it can meet immediate financial obligations without distress. Furthermore, the Return on Equity stands at -46.7% and the Return on Assets is -21.9%, metrics that reveal management is currently utilizing shareholder capital and assets to generate losses rather than returns, a common characteristic for clinical-stage entities prior to approval of their therapeutic candidates.
Avaliação de valorização
The Trailing Twelve Month P/E Ratio is N/A due to negative earnings, while the Forward P/E is listed as -0.89, a divergence that implies earnings are expected to remain negative or that the valuation model relies on projected future profitability rather than historical performance. The Price to Book ratio is 0.26, indicating that the market values the company's equity at a significant discount to its book value, which often occurs when intangible assets like intellectual property and clinical pipeline potential are not fully captured on the balance sheet. Although the Price to Sales ratio is N/A, the EV/EBITDA stands at 0.53, an alternative valuation metric that suggests the enterprise value is priced relative to operating performance on a normalized basis, reflecting the low multiple typical for speculative biotech assets. The 52-Week High is $1.78 and the 52-Week Low is $0.96, placing the stock's recent trading range between these boundaries and highlighting the volatility inherent in small-cap biotechnology equities. The Beta is -0.26, a unique and anomalous coefficient that suggests the stock price moves inversely to the broader market or possesses a specific volatility profile that differs significantly from the standard positive correlation expected in equity markets.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A because the company is in a clinical development phase where historical year-over-year comparisons for growth rates are not yet applicable or meaningful. Since the company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, Boundless Bio, Inc. effectively reinvests all available resources, including its substantial cash reserves, back into research and development to advance its oncology pipeline rather than distributing income to shareholders. The absence of a dividend yield confirms that the company prioritizes capital expenditure for clinical trials and regulatory strategy over income generation for investors. Consequently, the overall growth and income profile is characterized by a total reliance on potential future value creation from the BBI-940 therapeutic candidate, with no current income stream or historical growth trajectory to evaluate against peers.